Share Name Share Symbol Market Type Share ISIN Share Description
Consort Medical Plc LSE:CSRT London Ordinary Share GB0000946276 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  6.00 0.83% 726.00 30,006 16:35:25
Bid Price Offer Price High Price Low Price Open Price
726.00 738.00 740.00 724.00 726.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 305.10 12.50 21.30 34.1 361
Last Trade Time Trade Type Trade Size Trade Price Currency
17:10:19 O 200 726.00 GBX

Consort Medical (CSRT) Latest News

More Consort Medical News
Consort Medical Takeover Rumours

Consort Medical (CSRT) Share Charts

1 Year Consort Medical Chart

1 Year Consort Medical Chart

1 Month Consort Medical Chart

1 Month Consort Medical Chart

Intraday Consort Medical Chart

Intraday Consort Medical Chart

Consort Medical (CSRT) Discussions and Chat

Consort Medical Forums and Chat

Date Time Title Posts
04/11/201907:44Consort Medical - Medical Devices137
17/11/201414:19Aesica acquisition bolsters growth prospects-

Add a New Thread

Consort Medical (CSRT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-11-15 17:10:19726.002001,452.00O
2019-11-15 16:35:25726.001179.86UT
2019-11-15 16:24:30738.005043,719.52AT
2019-11-15 16:24:15737.402001,474.80O
2019-11-15 15:33:04730.001531,116.90O
View all Consort Medical trades in real-time

Consort Medical (CSRT) Top Chat Posts

DateSubject
15/11/2019
08:20
Consort Medical Daily Update: Consort Medical Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker CSRT. The last closing price for Consort Medical was 720p.
Consort Medical Plc has a 4 week average price of 702p and a 12 week average price of 702p.
The 1 year high share price is 1,100p while the 1 year low share price is currently 700p.
There are currently 49,733,065 shares in issue and the average daily traded volume is 165,113 shares. The market capitalisation of Consort Medical Plc is £361,062,051.90.
21/8/2019
09:38
cerrito: Thanks for that BigBloke. As you say share price performance very disappointing and the current price the same as at May 18th 2007 when I made my first purchase at 749.77. I do not see the Chairman instigating a shake up of Management nor indeed do I see major shareholders like Invesco, Polar and Schroders agitating for change; as he has been in post since April if he was going to do it I feel he would have done it by now…although it is possible but to my mind very unlikely that the fire showed up very serious management failings.Just a gut feeling and I may be wrong and indeed will be interesting to see the voting figures at the AGM. All the strategic decisions you highlight would have been signed off by the Board and they are not blameless. Indeed I have just caught up with Carlo whose shares have been suspended because they cannot produce financials due to problems in their automotive division which makes one wonder why the CSRT ever got it into their head to make a tentative bid to buy the whole company; I did not give it much attention at the time as I had so few shares but very spooky-albeit that there has been a subsequent change of Chairman. You mention the sale of King=and of course they want to get back into the US;that said the reasons for the sale they gave at the time seemed logical to me. As per my 132 I see CSRT as a good target for private equity. As a matter of interest when did they can their R&D activities the previous time?
16/8/2019
23:51
bigbloke: Not sure how much longer the current management teams at Consort and Bespak may have left before the new Chairman is forced to make some sweeping changes. The current fall in share price is returning the company to levels not seen in over a decade. Its growth of the Cambridge based innovation centre, whilst having produced some tangible results, is beginning to feel like the organisation of old - pre name change to Consort, when the previous R&D function was en masse removed due to it being overblown and costly. Jon Glenn's turnaround strategy seems to be failing. Purchasing of Aesica and divestment of King Systems has not made much of an impression. The total organisation is bigger, but the net value is now smaller than that seen in a long while. Very concerned that a take over is not far away...
13/6/2019
16:13
cerrito: Have to look at the results in detail but the share price reaction seems about right. I see that RBC has an as of today an outperform at 1130p
02/5/2019
22:21
cerrito: Thanks Typo56 for unearthing that in your 124. If the market felt something was cooking, I suspect that the price would be higher. I have to confess I have never heard of the German company Given the current FX rate and share price, as well as what it is up to and it's shareholder base, it would not surprise me at all if there was an offer but such a possibility plays little part in my decision to maintain my holding in the company.
31/1/2019
12:56
haroldthegreat: This should move the share price. in the uk the generics are selling well. when launched in the us should produce large volume orders . if first generic to market .....
02/12/2011
15:52
cerrito: Not had time to have a good look at yesterday's figures but note the following comment from The Independant Consort Medical Our view: Buy Share price: 530p (+32p) The market was certainly pleased with Consort Medical's update yesterday. The medical-devices firm issued half-yearly figures, which sent its stock up sharply on the day. Revenues in the six months to the end of October were up 5 per cent at nearly £69m, while pre-tax profits were up more than 50 per cent (profits before tax and special items were up 22 per cent). The group, which maintained its interim dividend at 7p per share, was boosted by strong volumes at its Bespak unit's core respiratory division. Net debt was up, as Consort pressed on with its planned investment activities, but, at 1.3 times earnings before interest, tax, depreciation and amortisation, it remains within the company's borrowing covenants and facilities. So, not much to fault. Although the economy both here and in many other parts of the world is not doing great, Consort remains confident, which shouldn't come as a surprise given the size and the trends in the broader market for respiratory illnesses. Not that the company is being complacent; yesterday, it also announced a contract to develop a device that looks like a cigarette and acts as a replacement for nicotine. This is also a growing area, and Consort's efforts in this direction are encouraging. At just under 11 times forward earnings, with a dividend yield of just under 4 per cent, the stock is also affordable.
Consort Medical share price data is direct from the London Stock Exchange
Your Recent History
LSE
CSRT
Consort Me..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191116 01:11:35